Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,740 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (capsule) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Between ABT-335, Rosuvastatin and Warfarin

NCT00487136
View directory record Official record
Conditions
Healthy
Interventions
Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

NCT01147744
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

NCT02886728
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 3 Interventional

First Line Hepato Cellular Carcinoma (HCC)

NCT00858871
View directory record Official record
Conditions
Hepato Cellular Carcinoma (HCC)
Interventions
Brivanib, Placebo, Sorafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Downey, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

NCT00212381
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
di indolylmethane (DIM), Red rice bran
Drug · Dietary Supplement
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

NCT02947893
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth
Drug
Lead sponsor
Georgetown University
Other
Eligibility
50 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2 Interventional

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT05536414
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Centanafadine, Escitalopram, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 27, 2026, 7:43 AM EDT
Terminated Phase 3 Interventional Results available

Stanford Accelerated Recovery Trial (START)

NCT01067144
View directory record Official record
Conditions
Pain, Breast Cancer, Lung Cancer
Interventions
Gabapentin, Lorazepam (active control), Placebo (inactive)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Sildenafil Exercise: Role of PDE5 Inhibition

NCT04039087
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil 40mg oral capsule, Placebo Oral capsule
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
9 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

NCT02360371
View directory record Official record
Conditions
Opioid Sensitivity, Individual Difference, Abuse Opioids
Interventions
Within-subject test of blinded study medication
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study of Debio 1450 in Healthy Subjects

NCT02162199
View directory record Official record
Conditions
Bacterial Infections
Interventions
Debio 1450, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease

NCT01983826
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Sodium Nitrate, Placebo
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of SRX246 Capsules in Healthy Adult Volunteers

NCT00910455
View directory record Official record
Conditions
Healthy
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

NCT02395978
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule, placebo
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508
View directory record Official record
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 27, 2026, 7:43 AM EDT
Not listed Phase 1 Interventional

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

NCT06309147
View directory record Official record
Conditions
Parkinson Disease
Interventions
BMS-9894923
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 27, 2026, 7:43 AM EDT
Not yet recruiting Phase 2 Interventional

NAC-REPAIR for Post-surgical Pain

NCT07227649
View directory record Official record
Conditions
Carpal Tunnel Surgery, Trigger Finger Disorder, De Quervain Syndrome, Guyon's Canal, Dupuytren Contracture, Morton Neuroma, Tarsal Tunnel Syndrome, Plantar Fasciopathy, Peroneal Nerve Entrapment
Interventions
NAC, NAC 0mg/day (Placebo)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

NCT03247543
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 200mg SPN-812, 400mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

NCT00627276
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 27, 2026, 7:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults

NCT07824271
View directory record Official record
Conditions
Healthy Participants Study
Interventions
ALZ-507, Placebo
Drug
Lead sponsor
Alzheon Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

NCT01298999
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
YF476, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 27, 2026, 7:43 AM EDT